Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-08-14 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. Form 8.3 is a mandatory disclosure required when a person holding interests in relevant securities representing 1% or more makes a dealing during a takeover offer. This type of disclosure relates to insider transactions or significant ownership changes during a takeover scenario. This aligns most closely with Director's Dealing (DIRS) or a specific type of regulatory filing related to takeovers. Since the definitions provided do not have a specific 'Takeover Disclosure' code, and this document details personal share transactions/interests by a major holder (Millennium International Management LP) in the context of an offer, it is best classified under Director's Dealing (DIRS) as it concerns insider/significant shareholder transactions, or as a Regulatory Filing (RNS) if DIRS is too narrow. Given the specific nature of the disclosure (Rule 8.3 related to a takeover), it is a highly specific regulatory filing concerning ownership/dealing. However, looking at the provided definitions, 'Director's Dealing (DIRS)' covers 'Report of personal share transactions by company directors and executives (insider trades)'. While Millennium is a fund manager, the spirit of the disclosure is reporting significant dealings/interests, which is closely related to insider trading disclosures. Since it is a formal regulatory disclosure mandated by the Takeover Code, RNS is a strong fallback, but DIRS captures the essence of reporting personal/significant dealings. Given the context of a takeover and the specific form number, it is a specialized regulatory filing. I will classify it as DIRS because it details dealings and interests of a major holder, which is analogous to insider dealing reports, and it is more specific than the general RNS fallback.
2023-08-14 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number'. It details an acquisition or disposal of voting rights by JPMorgan Chase & Co. in Dechra Pharmaceuticals PLC, crossing a notification threshold (8.315971%). This specific regulatory form (TR-1) is used in the UK/EU markets to report changes in major shareholdings, which falls under the category of Major Shareholding Notification (MRQ) in the provided definitions, as it reports changes in significant ownership levels crossing thresholds. The presence of the RNS header confirms it is a regulatory announcement.
2023-08-11 English
Form 8.3 - Dechra Pharmaceuticals plc
M&A Activity Classification · 98% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure/Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of disclosure relates to insider dealings or significant ownership changes during a takeover/merger event. Among the provided categories, 'M&A Activity' (TAR) is the closest fit as it covers merger proposals or takeover bids, and Form 8.3 is a mandatory filing during such an event. It is not a general Director's Dealing (DIRS) as it is specifically tied to the Takeover Code rules during an offer period.
2023-08-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'TR-1: Standard form for notification of major holdings' concerning an acquisition or disposal of voting rights by Societe Generale, crossing a threshold. This type of mandatory disclosure regarding changes in significant share ownership falls directly under the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-08-10 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure/Dealing Disclosure by a person with interests representing 1% or more in relevant securities during a takeover situation. This type of filing relates to insider transactions or significant ownership changes during a takeover bid, which falls under the scope of director/insider dealings or major shareholding notifications, but specifically within the context of a takeover. Given the options, 'Director's Dealing' (DIRS) is the closest fit for reporting personal transactions/interests by significant parties during a takeover, as it captures insider/significant shareholder activity. However, since this is a specific regulatory disclosure related to a takeover bid (Rule 8.3), it is a specialized form of insider/shareholder disclosure. Comparing DIRS (Director's Dealing) and MRQ (Major Shareholding Notification), Form 8.3 is more specific to takeover activity. Since there isn't a specific 'Takeover Disclosure' code, and it details interests and dealings of a significant party (Millennium International Management LP) in relation to an offeror/offeree, it is best classified as a specialized form of insider dealing/shareholding disclosure. DIRS is the most appropriate category for reporting personal share transactions by executives/insiders, which this disclosure details for a major shareholder during a takeover context. If the document were purely about a change in ownership crossing a threshold outside a takeover, MRQ might apply, but the explicit reference to the Takeover Code points towards DIRS as the best fit among the provided options for reporting significant party dealings/positions during an offer.
2023-08-10 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 96% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used to disclose interests and dealings in securities during a takeover offer. This specific type of disclosure relates to insider/significant shareholder activity during a M&A event, which aligns closely with the scope of takeover/merger activity. Reviewing the definitions: - 10-K, AR, IR are financial reports. - ER, CT are earnings related. - DIRS is Director's Dealing (insider trades), but Form 8.3 is specifically tied to the Takeover Code during an offer period, making it more specific than general insider trading reports. - TAR (M&A Activity) covers merger proposals or takeover bids. Form 8.3 is a mandatory disclosure *during* an active takeover situation involving Dechra Pharmaceuticals plc. While it involves share dealings by a major holder (similar to DIRS), the context (Rule 8.3 of the Takeover Code) places it squarely within the regulatory framework surrounding a takeover bid. Therefore, the most appropriate classification is M&A Activity (TAR), as this disclosure is a direct consequence of a takeover situation. However, upon re-evaluation against the provided codes, there isn't a specific code for 'Takeover Disclosure Form'. We must choose the best fit: 1. DIRS (Director's Dealing): This is a major shareholder/fund manager, not necessarily a director, but it is a dealing disclosure. 2. TAR (M&A Activity): This is directly related to a takeover situation. 3. RNS (Regulatory Filings): This is the fallback. Given that Form 8.3 is a mandatory filing under the Takeover Code, it is a regulatory filing related to a specific M&A event. Since TAR covers 'merger proposals or takeover bids', and this document is a required disclosure *during* such an event, TAR is the strongest thematic fit over the general DIRS or the catch-all RNS. If a specific 'Takeover Disclosure' code existed, it would be used, but TAR captures the underlying corporate action driving this filing.
2023-08-09 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.